Tearsheet

Hims & Hers Health (HIMS)

Market Price (4/11/2026): $19.43 | Market Cap: $4.4 Bil
Sector: Health Care | Industry: Health Care Services

Hims & Hers Health (HIMS)

Market Price (4/11/2026): $19.43
Market Cap: $4.4 Bil
Sector: Health Care
Industry: Health Care Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 59%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, E-commerce & Digital Retail, and Precision Medicine. Themes include Telehealth Platforms, Show more.

Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 42x, P/EPrice/Earnings or Price/(Net Income) is 34x

High stock price volatility
Vol 12M is 101%

Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31%

Key risks
HIMS key risks include [1] significant regulatory scrutiny and legal challenges over its marketing of compounded GLP-1 weight loss drugs and [2] difficulty achieving consistent profitability due to intense marketing spend and margin pressure from its personalized offerings.

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 59%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68%
3	Megatrend and thematic drivers Megatrends include Digital Health & Telemedicine, E-commerce & Digital Retail, and Precision Medicine. Themes include Telehealth Platforms, Show more.
4	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 42x, P/EPrice/Earnings or Price/(Net Income) is 34x
5	High stock price volatility Vol 12M is 101%
6	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 31%
7	Key risks HIMS key risks include [1] significant regulatory scrutiny and legal challenges over its marketing of compounded GLP-1 weight loss drugs and [2] difficulty achieving consistent profitability due to intense marketing spend and margin pressure from its personalized offerings.

Valuation, Metrics & Events

	4/11/26	2025	2024	2023	2022
Share Price CYE	$19.43	$29.55	$15.47	$9.92	$5.33
Market Cap CYE ($ Bil)	4.4	6.6	3.3	2.1	1.1
Total Debt ($ Bil)	1.1	0.1	0.0	0.0	0.0
Total Cash ($ Bil)	0.6	0.3	0.2	0.2	0.2
Enterprise Value ($ Bil)	5.0	6.7	3.3	2.1	1.1
Valuation Ratios
P/S TTM	1.9	3.7	3.4	3.3	3.4
P/EBIT TTM	41.8	59.7	-398.5	-32.6	-12.9
P/E TTM	34.4	39.9	-1,404.6	-34.5	-14.9
P/FCF TTM	76.8	27.7	63.6	-336.6	-24.9
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/11/26	2025	2024
Share Price CYE	$19.43	$29.55	$15.47
Market Cap CYE ($ Bil)	4.4	6.6	3.3
Total Debt ($ Bil)	1.1	0.1	0.0
Total Cash ($ Bil)	0.6	0.3	0.2
Enterprise Value ($ Bil)	5.0	6.7	3.3
Valuation Ratios
P/S TTM	1.9	3.7	3.4
P/EBIT TTM	41.8	59.7	-398.5
P/E TTM	34.4	39.9	-1,404.6
P/FCF TTM	76.8	27.7	63.6
Sector Ratios
P/S TTM (Sector)	3.8	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	HIMS	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	2.3
Rev Chg Q	28.4%	7.5%
Rev Chg LTM	59.0%	6.8%
Rev Chg 3Y Avg	64.6%	5.7%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.1
CFO LTM ($ Bil)	0.3
Net Inc LTM ($ Bil)	0.1
Op Mgn LTM	4.5%	18.6%
CFO/Rev LTM	12.8%	20.6%
Net Inc Mgn	5.5%	12.8%
VALUATION	HIGH
P/S	1.9	3.2
P/CFO	14.7	15.4
P/FCF	76.8	19.8
P/E	34.4	24.1
STABILITY	VERY GOOD
Debt/Equity	0.25	0.21
Cash/Assets	0.27	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Subscribers	2470000	9302025	Link
Monthly Online Revenue per Average Subscriber	80	9302025	Link
Subscribers using personalized solutions growth (YoY)	50%	11042025	Link

Upcoming
5/04/2026	Earnings Release	Rev: $617 Mil (E) EPS: $0.02 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Hims & Hers Health (HIMS) stock has lost about 40% since 12/31/2025 because of the following key factors:

1. Regulatory and Legal Crackdown on Compounded GLP-1 Medications.

Hims & Hers Health experienced a significant stock decline due to a series of regulatory and legal challenges regarding its compounded GLP-1 weight-loss medications. On February 7, 2026, the FDA issued a warning against Hims' $49 compounded oral semaglutide pill, labeling it an "illegal copycat" and citing concerns over quality and safety. This led to Hims withdrawing the product. Two days later, on February 9, 2026, Novo Nordisk filed a patent infringement lawsuit against Hims over compounded semaglutide, forcing the company to cancel its newly launched Wegovy alternative. These events significantly impacted Hims' growth strategy, which relied heavily on compounded GLP-1 offerings, and resulted in a 14.1% drop in after-hours trading on February 7, 2026, and a 17.8% intraday drop on February 9, 2026.

2. Weak Q1 2026 Revenue Guidance.

Despite beating Q4 2025 earnings per share estimates with $0.08 (compared to an estimated range of $0.02 to $0.05), and achieving a 28% year-over-year revenue increase to $617.8 million for Q4 2025, Hims & Hers provided a weaker-than-expected revenue guidance for Q1 2026. The company projected Q1 2026 revenue between $600 million and $625 million, which was below analysts' consensus estimates that ranged from approximately $621.4 million to $649 million. This cautious outlook on future revenue growth, coupled with a full-year 2026 revenue expectation of $2.7 billion to $2.9 billion, a sharp slowdown from 59% growth in 2025, contributed to negative investor sentiment.

Show more

Stock Movement Drivers

Fundamental Drivers

The -40.2% change in HIMS stock from 12/31/2025 to 4/10/2026 was primarily driven by a -37.4% change in the company's P/E Multiple.

(LTM values as of)	12312025	4102026	Change
Stock Price ($)	32.47	19.43	-40.2%
Change Contribution By:
Total Revenues ($ Mil)	2,211	2,348	6.2%
Net Income Margin (%)	6.1%	5.5%	-9.6%
P/E Multiple	54.9	34.4	-37.4%
Shares Outstanding (Mil)	226	227	-0.3%
Cumulative Contribution			-40.2%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/10/2026

	Return	Correlation
HIMS	-40.2%
Market (SPY)	-5.4%	28.4%
Sector (XLV)	-4.8%	21.7%

Fundamental Drivers

The -65.7% change in HIMS stock from 9/30/2025 to 4/10/2026 was primarily driven by a -47.7% change in the company's P/E Multiple.

(LTM values as of)	9302025	4102026	Change
Stock Price ($)	56.72	19.43	-65.7%
Change Contribution By:
Total Revenues ($ Mil)	2,014	2,348	16.6%
Net Income Margin (%)	9.6%	5.5%	-43.1%
P/E Multiple	65.7	34.4	-47.7%
Shares Outstanding (Mil)	224	227	-1.2%
Cumulative Contribution			-65.7%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/10/2026

	Return	Correlation
HIMS	-65.7%
Market (SPY)	-2.9%	33.2%
Sector (XLV)	6.3%	11.6%

Fundamental Drivers

The -34.2% change in HIMS stock from 3/31/2025 to 4/10/2026 was primarily driven by a -35.9% change in the company's Net Income Margin (%).

(LTM values as of)	3312025	4102026	Change
Stock Price ($)	29.55	19.43	-34.2%
Change Contribution By:
Total Revenues ($ Mil)	1,477	2,348	59.0%
Net Income Margin (%)	8.5%	5.5%	-35.9%
P/E Multiple	51.4	34.4	-33.1%
Shares Outstanding (Mil)	219	227	-3.5%
Cumulative Contribution			-34.2%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/10/2026

	Return	Correlation
HIMS	-34.2%
Market (SPY)	16.3%	34.1%
Sector (XLV)	2.3%	13.9%

Fundamental Drivers

The 95.9% change in HIMS stock from 3/31/2023 to 4/10/2026 was primarily driven by a 1478.2% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4102026	Change
Stock Price ($)	9.92	19.43	95.9%
Change Contribution By:
Total Revenues ($ Mil)	149	2,348	1478.2%
P/S Multiple	2.4	1.9	-20.3%
Shares Outstanding (Mil)	35	227	-84.4%
Cumulative Contribution			95.9%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/10/2026

	Return	Correlation
HIMS	95.9%
Market (SPY)	63.3%	35.6%
Sector (XLV)	19.1%	16.7%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
HIMS Return	-55%	-2%	39%	172%	34%	-39%	35%
Peers Return	30%	3%	-8%	0%	20%	2%	51%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
HIMS Win Rate	25%	58%	50%	67%	50%	25%
Peers Win Rate	60%	52%	40%	52%	62%	55%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
HIMS Max Drawdown	-62%	-53%	-10%	-7%	0%	-55%
Peers Max Drawdown	-9%	-21%	-23%	-17%	-9%	-6%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, CVS, CI, LH, DGX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	HIMS	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-87.3%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	686.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	769 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-14.7%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	17.3%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	40 days	148 days

Compare to ADUS, CVS, CI, LH, DGX

In The Past

Hims & Hers Health's stock fell -87.3% during the 2022 Inflation Shock from a high on 2/8/2021. A -87.3% loss requires a 686.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Hims & Hers Health (HIMS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

AI Analysis | Feedback

Here are 2 brief analogies for Hims & Hers Health:

It's like Teladoc Health combined with a modern online pharmacy and wellness store for personal care needs.
It's the Dollar Shave Club for online prescriptions and wellness products related to hair loss, skincare, and sexual health.

AI Analysis | Feedback

Telehealth Platform & Medical Consultations: A multi-specialty digital platform connecting consumers with licensed healthcare professionals for virtual consultations and ongoing care.
Prescription Medications: Offers various prescription drugs on a recurring basis, often facilitated by provider consultations and ongoing support.
Over-the-Counter (OTC) Products: Provides a curated selection of non-prescription drugs, devices, cosmetics, and supplements for wellness, sexual health, skincare, and hair care.

AI Analysis | Feedback

Hims & Hers Health (HIMS) primarily sells its products and services directly to individual consumers.

The company serves the following categories of customers:

Wellness and General Health Customers: Individuals seeking general health and wellness products, including supplements like vitamin C, melatonin, biotin, and collagen protein, as well as medical consultation services for various health needs.
Sexual Health and Wellness Customers: Individuals looking for products and services related to sexual health, such as condoms, climax delay spray and wipes, vibrators, lubricants, and prescription medication for sexual health concerns.
Skincare and Hair Care Customers: Individuals seeking solutions for skincare issues, including moisturizers, serums, and face washes, and those looking for hair care products like shampoos, conditioners, scalp scrubs, and topical treatments such as minoxidil.

AI Analysis | Feedback

Truepill (Private Company)

AI Analysis | Feedback

Andrew Dudum

Chief Executive Officer

Andrew Dudum co-founded Hims & Hers in 2016 and has served as its CEO since inception. He is also a co-founder of Atomic Labs, a startup studio and investment fund backed by prominent investors such as Peter Thiel and Marc Andreessen, where he played an integral role in developing over a dozen companies including Bungalow, Homebound, TalkIQ, and Terminal. Dudum is an active angel investor and advisor to various startup companies, including Cherubic Ventures. Prior to Atomic, he co-founded LendforPeace, a nonprofit microlending site. He also worked at TokBox, a video-chat startup that was subsequently acquired. Hims & Hers went public via a SPAC in 2020, debuting on the New York Stock Exchange in January 2021 at a $1.6 billion valuation.

Yemi Okupe

Chief Financial Officer

Yemi Okupe joined Hims & Hers as Chief Financial Officer in January 2022. He brings extensive experience from financial leadership positions at high-growth, B2C companies. From 2019 to 2021, Okupe served as Divisional CFO at Uber, where he was responsible for UberEats and Uber's global mobility unit. His career also includes various financial leadership roles at eBay and PayPal, including Divisional CFO of Braintree, and he was the finance lead for Google Payments and Google Express at Google. Prior to joining Hims & Hers, he served as CFO of Hipcamp.

Mike Chi

Chief Operating Officer

Mike Chi joined Hims & Hers in April 2021 as Chief Operating Officer. He possesses over 20 years of experience in consumer-focused businesses, specializing in brand positioning, growth marketing, product management, and merchandising strategy. Before his role at Hims & Hers, Chi was the Chief Marketing Officer at Zola, an online wedding planning platform. He also held positions as Vice President of Marketing and digital experience at INTERMIX and various senior roles in marketing and general management at Gilt Groupe.

Dr. Patrick Carroll

Chief Medical Officer

Dr. Patrick Carroll re-joined Hims & Hers as Chief Medical Officer in December 2022 and also serves as a board member. He previously held the CMO position at Hims & Hers from June 2019 through January 2022. Between his two tenures with Hims & Hers, Dr. Carroll was the Chief Medical Officer of Vida Health, a virtual care company. Prior to his initial role at Hims & Hers, he served for five years as Group Vice President and Chief Medical Officer of Walgreens, where he oversaw retail clinics, healthcare strategy, and quality programs. His experience also includes CMO roles at Integrated Care Partners (Hartford HealthCare's clinical integration organization) and Granite Medical Group.

Dheerja Kaur

Chief Product Officer

Dheerja Kaur joined Hims & Hers in July 2025 as Chief Product Officer. She brings nearly two decades of experience in building category-defining products and services. Most recently, she served as VP of Product at Robinhood, where she was instrumental in scaling their business and led Robinhood Gold, a premium membership offering that reached over 3 million subscribers. She also previously held the position of Chief Product Officer at The Skimm.

AI Analysis | Feedback

The key risks to Hims & Hers Health (HIMS) include regulatory and legal scrutiny, intense competition, and challenges related to its reliance on compounded medications. *

Regulatory and Legal Scrutiny

Hims & Hers Health faces significant regulatory scrutiny from the U.S. Food and Drug Administration (FDA) and other bodies, particularly concerning its compounded medication offerings and marketing practices. The FDA has issued warning letters to telehealth companies, including Hims & Hers, for promoting compounded versions of GLP-1 weight-loss drugs with misleading claims. This regulatory action forced Hims & Hers to withdraw its discounted version of Novo Nordisk's GLP-1 therapy, Wegovy, in the past. While a recent partnership with Novo Nordisk to offer branded GLP-1 medications has eased some legal and regulatory overhangs, the ongoing FDA scrutiny of compounded weight-loss drugs remains a structural risk to the company's business model. The company has also faced a U.S. Securities and Exchange Commission (SEC) investigation. *

Intense Competition

The telehealth and direct-to-consumer healthcare sectors are highly competitive, with Hims & Hers facing numerous rivals. Direct competitors like Ro (Roman) and Keeps offer similar direct-to-consumer models, competing on factors such as pricing, brand recognition, and the range of health offerings. Broader telehealth platforms such as Teladoc Health also present a significant competitive challenge. This intense market environment necessitates continuous innovation and efficient operations, potentially pressuring pricing and profitability. *

Reliance on Compounded Medications and Market Shifts

Hims & Hers' growth has been significantly accelerated by its expansion into offerings such as GLP-1 weight loss treatments, which historically included compounded versions of these drugs. However, regulatory changes and increased enforcement, particularly regarding compounded GLP-1 medications, have compromised this strategy. The expiration of COVID-19-era telehealth waivers and evolving regulations concerning compounded drugs create a complex compliance landscape. While the company is adapting by partnering with pharmaceutical manufacturers for branded products, the capital and effort invested in compounding infrastructure may generate poor returns as the company navigates this transition. This shift could also impact their growth trajectory and margins if branded GLP-1s consolidate power back to pharmaceutical-controlled channels.

AI Analysis | Feedback

The aggressive expansion of Amazon (through Amazon Clinic and Amazon Pharmacy) into direct-to-consumer telehealth consultations and online prescription medication fulfillment represents a clear emerging threat. Amazon's vast logistics network, established customer base, and ability to offer competitive pricing could significantly disrupt Hims & Hers Health's core business model of connecting consumers to healthcare professionals and delivering prescription and over-the-counter products directly to them.

AI Analysis | Feedback

Addressable Markets for Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates in several significant addressable markets related to telehealth, prescription medication, over-the-counter products, and health and wellness supplements. The market sizes for their main products and services are as follows:

Telehealth Platform: The U.S. telehealth market size is estimated at approximately USD 52.77 billion in 2025 and is projected to reach around USD 447.69 billion by 2035.
Sexual Health and Wellness: The U.S. sexual wellness market is estimated at USD 23.25 billion in 2025 and is projected to reach approximately USD 49.92 billion by 2035.
Skincare: The U.S. skincare market is estimated to be around USD 24 billion in annual revenue in 2025 and is expected to grow to USD 30.60 billion by 2030.
Hair Care: The U.S. hair care market size is valued at USD 20.12 billion in 2025, estimated at USD 20.98 billion in 2026, and projected to reach USD 25.9 billion by 2031.
Wellness Supplements: The North America dietary supplements market, which includes wellness supplements, is estimated at USD 64.06 billion in 2025 and is projected to reach USD 91.30 billion by 2030.
Over-the-Counter (OTC) Drugs: The U.S. over-the-counter (OTC) drugs market size is estimated at USD 54.6 billion in 2025 and is expected to grow to USD 86.3 billion by 2034.
Direct-to-Consumer (DTC) Weight-Loss Medication: The global direct-to-consumer (DTC) weight-loss medication market size is valued at USD 8.64 billion in 2025 and is estimated to reach USD 35.61 billion by 2034. North America holds the largest share of this market.

AI Analysis | Feedback

Hims & Hers Health (HIMS) is expected to drive future revenue growth over the next 2-3 years through several key strategies: * Expansion into New Therapeutic Categories and Personalized Treatments: The company anticipates significant revenue growth from expanding its offerings into new health specialties. This includes the substantial growth propelled by its weight management category, with projections for it to be a primary driver of revenue. Further expansion into hormonal health, specifically menopause and low testosterone treatments, is also a key focus, targeting large market opportunities in the United States. Additionally, the integration of lab testing is expected to broaden personalized treatment options, and the overall strategy involves evolving personalized solutions to encompass multi-condition treatments and new form factors, aiming for continued market share gains and enhanced patient lifetime value. * International Market Expansion: Hims & Hers is actively pursuing a global expansion strategy to enhance its market position. This involves strategic acquisitions, such as ZAVA in Europe (extending its footprint across the U.K., Germany, France, and Ireland) and Eucalyptus (expanding presence into regions like Australia and Japan). The company also plans entry into new geographies, including Canada in 2026, which is expected to make weight loss treatments more accessible. Management has set an ambitious goal to scale its international business to over $1 billion in annual revenue within three years, with at least $200 million in revenue contributions projected from international markets in 2026. * Subscriber Growth and Enhanced Customer Engagement: A core driver of revenue growth is the continuous expansion of the company's subscriber base and increasing the monthly revenue generated per average subscriber. This is achieved through effective user acquisition strategies, robust retention initiatives, and broadening the array of product and service offerings available on its direct-to-consumer platform. The company's business model is largely subscription-based, indicating a high degree of recurring revenue and customer loyalty. * Strategic Partnerships for Branded Medications: Hims & Hers is strengthening its market position through strategic collaborations with pharmaceutical companies. A notable example is its partnership with Novo Nordisk to distribute branded weight-loss medicines, such as Ozempic and Wegovy. This move signifies a shift from reliance on compounded drugs to officially offering brand-name medications, which is anticipated to bolster credibility, expand treatment options, attract more customers, and drive significant revenue growth by enhancing user trust and platform stickiness.

AI Analysis | Feedback

Share Repurchases

Hims & Hers Health authorized a new share repurchase program of up to $250 million of its Class A common stock in November 2025, effective through November 11, 2028.
This new program followed the completion of a prior $100 million share repurchase program, which commenced in July 2024.
The company repurchased $89.96 million in shares in 2025 and $83.039 million in 2024.

Share Issuance

Hims & Hers Health became a public company in January 2021 through a merger with Oaktree Acquisition Corp. II, a Special Purpose Acquisition Company (SPAC), which brought in nearly $280 million for expansion initiatives.
In 2025, the company recorded $970 million in proceeds from the issuance of convertible senior notes, net of debt discount.

Inbound Investments

In January 2019, Hims raised $100 million in a Series C funding round, which valued the company at $1 billion pre-money.
The SPAC merger in January 2021 injected approximately $280 million into the company for growth and expansion efforts.

Outbound Investments

In February 2026, Hims & Hers acquired Eucalyptus, an Australian digital health platform operating Juniper, Pilot, and Kin, in a deal valued at $1.6 billion. The acquisition involved an initial cash payment of approximately $240 million, with the remainder paid over 18 months.
In June 2025, the company acquired ZAVA, a European digital health platform, which expanded its presence in the U.K., Germany, France, and Ireland through an all-cash transaction.
Hims & Hers also acquired London-based Honest Health in 2021.

Capital Expenditures

Capital expenditures for Hims & Hers Health peaked at $226 million in fiscal year 2025, increasing significantly from $41.655 million in 2024, $17.22 million in 2023, and $2.714 million in 2022.
The company anticipates continued investment in existing and new offerings, AI-driven tools, and international expansion in 2026.
Hims & Hers entered a long-term lease for a large facility in New Albany, Ohio, designated for office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities.

Interactive Breakdown

null

null

Better Bets vs. Hims & Hers Health (HIMS)

CVS Health

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for HIMS: 64.6% | 1.9x)

ESPR (87.0% | 1.3x)

Esperion Therapeutics

IPSC (564.8% | 1.8x)

Century Therapeutics

ATRA (437.1% | 0.5x)

Atara Biotherapeutics

SBFM (167.8% | 0.1x)

Sunshine Biopharma

NXGL (81.2% | 0.4x)

NexGel

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HIMS: 64.6% | 41.8x)

ARWR (14468.6% | 29.7x)

Arrowhead Pharmaceuticals

TGTX (2807.1% | 37.9x)

TG Therapeutics

TMDX (92.8% | 35.9x)

TransMedics

ANAB (218.6% | 40.7x)

AnaptysBio

ESPR (87.0% | 8.5x)

Esperion Therapeutics

Higher Rev Chg LTM (Value for HIMS: 59.0%)

MDGL (432.1%)

Madrigal Pharmaceuticals

BBIO (126.3%)

BridgeBio Pharma

INSM (66.7%)

Insmed

AXSM (65.5%)

Axsome Therapeutics

ALNY (65.2%)

Alnylam Pharmaceuticals

Higher Rev Chg 3Y Avg (Value for HIMS: 64.6%)

ARWR (14468.6%)

Arrowhead Pharmaceuticals

IBRX (1032.7%)

ImmunityBio

BBIO (774.5%)

BridgeBio Pharma

AXSM (183.0%)

Axsome Therapeutics

CYTK (143.3%)

Cytokinetics

Higher Op Mgn LTM (Value for HIMS: 4.5%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

AMGN (24.7%)

Amgen

Higher CFO/Rev LTM (Value for HIMS: 12.8%)

ABBV (31.1%)

AbbVie

AMGN (27.1%)

Amgen

JNJ (26.0%)

Johnson & Johnson

LLY (25.8%)

Eli Lilly

MRK (25.3%)

Merck

Higher FCF/Rev LTM (Value for HIMS: 2.4%)

ABBV (29.1%)

AbbVie

JNJ (20.5%)

Johnson & Johnson

MRK (19.0%)

Merck

LLY (9.2%)

Eli Lilly

UNH (3.6%)

UnitedHealth

Higher Total Yield (Value for HIMS: 2.9%)

MRK (8.8%)

Merck

UNH (7.2%)

UnitedHealth

JNJ (6.8%)

Johnson & Johnson

ABBV (4.3%)

AbbVie

LLY (3.1%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for HIMS: 64.6% | 1.9x)

SLF (322.2% | 0.9x)

Sun Life Financial

SMCI (66.3% | 0.5x)

Super Micro Computer

ROOT (78.0% | 0.5x)

Root

REAX (73.2% | 0.3x)

Real Brokerage

ACTG (80.7% | 1.7x)

Acacia Research

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HIMS: 64.6% | 41.8x)

NVDA (101.8% | 35.2x)

NVIDIA

APO (66.8% | 7.5x)

Apollo Global Management

TKO (77.1% | 18.5x)

TKO

SMCI (66.3% | 14.6x)

Super Micro Computer

ORLA (81.9% | 19.6x)

Orla Mining

Higher Rev Chg LTM (Value for HIMS: 59.0%)

CRWV (167.9%)

CoreWeave

MU (85.5%)

Micron Technology

AU (70.8%)

Anglogold Ashanti

NVDA (65.5%)

NVIDIA

APP (61.1%)

AppLovin

What You Pay

P/EBIT (Value for HIMS: 41.8x)

RPRX (12.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.0x)

Veeva Systems

HALO (16.5x)

Halozyme Therapeutics

UTHR (14.3x)

United Therapeutics

CPRX (11.9x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (18.1x)

ResMed

AMGN (16.1x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for HIMS: 34.4x)

RPRX (26.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.3x)

Veeva Systems

HALO (25.2x)

Halozyme Therapeutics

UTHR (18.6x)

United Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (22.5x)

ResMed

AMGN (24.5x)

Amgen

PBH (14.5x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for HIMS: 64.6%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for HIMS: 59.0%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for HIMS: 28.4%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for HIMS: 7.1%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	HIMS Stock (+41%): Novo Nordisk GLP-1 Deal Ends Lawsuit — Market Rerates	03/10/2026
2	Hims & Hers Stock Pre-Market (+40%): Ends Novo Nordisk Feud with Weight-Loss Drug Deal	03/07/2026
3	Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze	03/03/2026
4	HIMS Stock Falls -47% With A 10-day Losing Spree On FDA Crackdown	02/13/2026
5	HIMS Stock Falls -44% With A 9-day Losing Spree On FDA Crackdown	02/12/2026
6	HIMS Stock Falls -42% On FDA Crackdown & Novo Nordisk Lawsuit	02/11/2026
7	Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA	02/10/2026
8	HIMS Stock Falls -35% With A 7-day Losing Spree On Novo Lawsuit & FDA Action	02/10/2026
9	Hims & Hers Stock Pre-Market (-16%) : DOJ Probe & FDA Crackdown on Weight-Loss Drugs	02/07/2026
10	HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns	01/01/2026
11	ARTICLES
12	Why Is HIMS Stock Down 40%?	04/10/2026
13	Hims & Hers Stock Pre-Market (+40%): Ends Novo Nordisk Feud with Weight-Loss Drug Deal	03/07/2026
14	Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze	03/03/2026
15	HIMS Stock Falls -42% On FDA Crackdown & Novo Nordisk Lawsuit	02/11/2026
16	Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA	02/10/2026

	Title
0	DASHBOARDS
1	HIMS Stock (+41%): Novo Nordisk GLP-1 Deal Ends Lawsuit — Market Rerates
2	Hims & Hers Stock Pre-Market (+40%): Ends Novo Nordisk Feud with Weight-Loss Drug Deal
3	Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze
4	HIMS Stock Falls -47% With A 10-day Losing Spree On FDA Crackdown
5	HIMS Stock Falls -44% With A 9-day Losing Spree On FDA Crackdown
6	HIMS Stock Falls -42% On FDA Crackdown & Novo Nordisk Lawsuit
7	Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA
8	HIMS Stock Falls -35% With A 7-day Losing Spree On Novo Lawsuit & FDA Action
9	Hims & Hers Stock Pre-Market (-16%) : DOJ Probe & FDA Crackdown on Weight-Loss Drugs
10	HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns
11	ARTICLES
12	Why Is HIMS Stock Down 40%?
13	Hims & Hers Stock Pre-Market (+40%): Ends Novo Nordisk Feud with Weight-Loss Drug Deal
14	Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze
15	HIMS Stock Falls -42% On FDA Crackdown & Novo Nordisk Lawsuit
16	Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA

Trade Ideas

Select ideas related to HIMS.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	HIMS	ADUS	CVS	CI	LH	DGX	Median
Name	Hims & H.	Addus Ho.	CVS Heal.	Cigna	Labcorp	Quest Di.
Mkt Price	19.43	92.21	79.33	271.25	260.93	191.51	141.86
Mkt Cap	4.4	1.7	100.7	71.6	21.6	20.7	21.1
Rev LTM	2,348	1,423	402,067	274,588	13,952	11,035	12,493
Op Inc LTM	106	139	10,385	-	1,516	1,556	1,516
FCF LTM	57	104	7,807	8,389	1,206	1,359	1,282
FCF 3Y Avg	101	106	8,176	9,195	1,059	1,044	1,051
CFO LTM	300	112	10,639	9,601	1,640	1,886	1,763
CFO 3Y Avg	208	113	11,057	10,592	1,518	1,497	1,508

Growth & Margins

	HIMS	ADUS	CVS	CI	LH	DGX	Median
Name	Hims & H.	Addus Ho.	CVS Heal.	Cigna	Labcorp	Quest Di.
Rev Chg LTM	59.0%	23.2%	7.8%	12.5%	7.2%	11.8%	12.1%
Rev Chg 3Y Avg	64.6%	14.5%	7.7%	15.3%	3.5%	4.0%	11.1%
Rev Chg Q	28.4%	25.6%	8.2%	10.1%	5.6%	7.1%	9.1%
QoQ Delta Rev Chg LTM	6.2%	5.6%	2.0%	2.5%	1.4%	1.7%	2.3%
Op Mgn LTM	4.5%	9.7%	2.6%	-	10.9%	14.1%	9.7%
Op Mgn 3Y Avg	1.8%	9.1%	3.1%	-	9.6%	13.8%	9.1%
QoQ Delta Op Mgn LTM	-0.7%	0.6%	-0.1%	-	1.0%	-0.0%	-0.0%
CFO/Rev LTM	12.8%	7.8%	2.6%	3.5%	11.8%	17.1%	9.8%
CFO/Rev 3Y Avg	12.7%	9.5%	2.9%	4.6%	11.6%	14.8%	10.6%
FCF/Rev LTM	2.4%	7.3%	1.9%	3.1%	8.6%	12.3%	5.2%
FCF/Rev 3Y Avg	7.1%	8.9%	2.2%	4.0%	8.1%	10.3%	7.6%

Valuation

	HIMS	ADUS	CVS	CI	LH	DGX	Median
Name	Hims & H.	Addus Ho.	CVS Heal.	Cigna	Labcorp	Quest Di.
Mkt Cap	4.4	1.7	100.7	71.6	21.6	20.7	21.1
P/S	1.9	1.2	0.3	0.3	1.5	1.9	1.4
P/EBIT	41.8	11.8	19.2	7.8	16.2	13.0	14.6
P/E	34.4	17.4	57.0	12.0	24.6	20.8	22.7
P/CFO	14.7	15.0	9.5	7.5	13.1	11.0	12.1
Total Yield	2.9%	5.7%	5.1%	10.6%	5.2%	6.5%	5.5%
Dividend Yield	0.0%	0.0%	3.4%	2.2%	1.1%	1.7%	1.4%
FCF Yield 3Y Avg	2.3%	5.7%	9.7%	11.7%	5.4%	6.1%	5.9%
D/E	0.3	0.1	0.8	0.4	0.3	0.3	0.3
Net D/E	0.1	0.1	0.7	0.3	0.3	0.3	0.3

Returns

	HIMS	ADUS	CVS	CI	LH	DGX	Median
Name	Hims & H.	Addus Ho.	CVS Heal.	Cigna	Labcorp	Quest Di.
1M Rtn	-24.9%	-10.5%	4.8%	4.0%	-3.5%	-4.1%	-3.8%
3M Rtn	-38.7%	-16.0%	-0.4%	-2.2%	3.9%	10.8%	-1.3%
6M Rtn	-64.0%	-18.3%	3.5%	-8.8%	-5.6%	5.0%	-7.2%
12M Rtn	-27.5%	-9.4%	19.4%	-15.4%	20.6%	19.0%	4.8%
3Y Rtn	103.5%	-17.8%	16.8%	7.7%	14.7%	41.3%	15.8%
1M Excs Rtn	-25.5%	-11.1%	4.2%	3.4%	-4.1%	-4.7%	-4.4%
3M Excs Rtn	-41.1%	-16.4%	0.7%	-2.4%	4.2%	10.2%	-0.8%
6M Excs Rtn	-67.5%	-20.2%	3.9%	-11.5%	-6.4%	5.9%	-9.0%
12M Excs Rtn	-62.4%	-41.1%	-15.0%	-48.6%	-15.7%	-14.8%	-28.4%
3Y Excs Rtn	26.3%	-77.9%	-49.4%	-54.4%	-50.4%	-21.5%	-49.9%

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	2/23/2026	2/23/2026	2/24/2025	2/26/2024	2/27/2023	2/24/2022	2/27/2023
Key Financials
Total Revenue	2,348	2,348	1,477	872	527	272	149
EBITDA	160	160	79	-20	-61	-111	-14
Operating Income	106	106	62	-29	-69	-115	-15
Net Income	128	128	126	-24	-66	-108	-18
EPS	0.57	0.57	0.58	-0.11	-0.32	-0.58	-0.51
Growth Rates
Total Revenue Growth	59.0%	59.0%	69.3%	65.5%	93.8%	82.8%	80.2%
EBITDA Growth	102.7%	102.7%	496.2%	67.4%	44.8%	-687.7%	80.3%
Operating Income Growth	70.6%	70.6%	310.2%	57.1%	40.3%	-659.7%	79.6%
Net Income Growth	1.8%	1.8%	635.3%	64.1%	39.0%	-494.3%	74.9%
Margins
EBITDA Margin	6.8%	6.8%	5.3%	-2.3%	-11.6%	-40.8%	-9.5%
Operating Income Margin	4.5%	4.5%	4.2%	-3.4%	-13.0%	-42.3%	-10.2%
Net Income Margin	5.5%	5.5%	8.5%	-2.7%	-12.5%	-39.6%	-12.2%
Cash & Debt
Total Cash	577	577	300	221	180	247	100
Total Debt	1,121	1,121	11	10	5	5	0
Net Debt / (Cash)	543	543	-289	-211	-174	-242	-100
Cash Flows
Net Cash from Operations	300	300	251	73	-27	-34	-2
Free Cash from Operations	57	57	198	47	-34	-39	-7
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	90	90	83	2	-0	22	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	2/23/2026	11/3/2025	8/4/2025	5/5/2025	2/24/2025	11/4/2024	8/5/2024	5/6/2024	2/26/2024	11/6/2023	8/7/2023	5/8/2023
Key Financials Quarterly
Total Revenue	618	599	545	586	481	402	316	278	247	227	208	191
Ebitda	27	29	37	66	25	27	15	13	2	-6	-7	-9
Operating Income	9	12	27	58	19	22	11	10	-0	-9	-9	-11
Net Income	21	16	43	49	26	76	13	11	1	-8	-7	-10
EPS	0.09	0.07	0.19	0.22	0.12	0.35	0.06	0.05	0.01	-0.04	-0.03	-0.05
Key Financials TTM
Total Revenue TTM	2,348	2,211	2,014	1,784	1,477	1,242	1,067	959	872	793	711	616
Ebitda TTM	160	157	155	132	79	57	24	2	-20	-32	-44	-55
Operating Income TTM	106	115	126	110	62	43	12	-8	-29	-41	-52	-63
Net Income TTM	128	134	194	164	126	101	18	-2	-24	-36	-47	-59
Growth Rates Quarterly
Total Revenue Growth	28.4%	49.2%	72.6%	110.7%	95.1%	77.1%	51.8%	45.8%	47.5%	56.5%	83.1%	88.3%
EBITDA Growth	10.6%	10.2%	153.4%	412.8%	992.0%	532.2%	313.9%	241.1%	123.5%	65.8%	62.7%	39.7%
Operating Income Growth	-50.6%	-47.2%	142.3%	484.6%	4749.0%	361.6%	219.4%	187.9%	96.6%	57.2%	54.3%	33.4%
Net Income Growth	-20.8%	-79.1%	219.7%	344.7%	1990.4%	1098.9%	285.8%	210.5%	111.4%	59.8%	63.6%	38.1%
Margins Quarterly
EBITDA Margin	4.4%	4.9%	6.8%	11.3%	5.1%	6.7%	4.6%	4.6%	0.9%	-2.7%	-3.3%	-4.8%
Operating Income Margin	1.5%	2.0%	4.9%	9.9%	3.9%	5.6%	3.5%	3.6%	-0.2%	-3.8%	-4.4%	-5.9%
Net Income Margin	3.3%	2.6%	7.8%	8.4%	5.4%	18.8%	4.2%	4.0%	0.5%	-3.3%	-3.4%	-5.3%
Cash & Debt
Total Cash	577	630	1,145	323	300	254	227	204	221	212	193	184
Total Debt	1,121	1,118	1,044	63	11	11	11	12	10	5	5	5
Net Debt / (Cash)	543	488	-100	-259	-289	-243	-216	-192	-211	-208	-188	-179
Cash Flows Quarterly
FCF from Operations	61	149	-19	109	86	85	54	26	22	25	17	9
Cash Flows TTM
FCF from Operations TTM	300	325	262	334	251	187	127	90	73	45	26	2
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	80	9	-0	-0	5	30	20	28	2	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	3.1%	3.9%	17.4%	39.3%	17.3%	19.2%	8.9%	7.0%	-0.2%	-7.0%	-7.5%	-9.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	8.8%	9.6%	20.5%	22.8%	14.4%	9.2%	2.1%	-1.6%	-5.9%	-8.3%	-10.5%	-12.9%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	872	527	272
Total	872	527	272

Net Income by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	-24
Total	-24

Assets by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment				206	205
Total				206	205

Price Behavior

Price Behavior

Market Price	$19.43
Market Cap ($ Bil)	4.4
First Trading Date	09/13/2019
Distance from 52W High	-70.6%
	50 Days	200 Days
DMA Price	$20.14	$38.90
DMA Trend	down	down
Distance from DMA	-3.5%	-50.1%
	3M	1YR
Volatility	116.7%	100.3%
Downside Capture	1.99	1.56
Upside Capture	220.15	177.54
Correlation (SPY)	26.5%	30.2%

HIMS Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	5.90	3.17	2.57	2.48	1.83	2.13
Up Beta	3.09	0.59	0.29	1.13	1.25	1.08
Down Beta	6.57	3.00	2.35	2.59	2.18	2.19
Up Capture	1451%	324%	221%	130%	261%	8253%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	12	14	22	46	113	367
Down Capture	138%	298%	281%	241%	157%	113%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	10	28	40	79	137	374

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HIMS
HIMS	-27.1%	101.3%	0.14	-
Sector ETF (XLV)	12.3%	16.8%	0.52	12.6%
Equity (SPY)	31.2%	17.3%	1.47	32.1%
Gold (GLD)	60.1%	27.8%	1.69	3.9%
Commodities (DBC)	29.8%	16.6%	1.58	21.4%
Real Estate (VNQ)	21.3%	15.2%	1.07	15.7%
Bitcoin (BTCUSD)	-5.7%	43.7%	-0.01	19.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HIMS
HIMS	6.2%	83.7%	0.44	-
Sector ETF (XLV)	6.3%	14.6%	0.25	21.0%
Equity (SPY)	11.1%	17.0%	0.50	37.2%
Gold (GLD)	22.1%	17.8%	1.02	5.6%
Commodities (DBC)	11.8%	18.8%	0.52	8.3%
Real Estate (VNQ)	3.7%	18.8%	0.10	24.6%
Bitcoin (BTCUSD)	4.0%	56.5%	0.29	19.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with HIMS
HIMS	6.9%	76.9%	0.47	-
Sector ETF (XLV)	9.8%	16.5%	0.48	16.3%
Equity (SPY)	13.8%	17.9%	0.66	28.0%
Gold (GLD)	14.2%	15.9%	0.74	5.7%
Commodities (DBC)	8.6%	17.6%	0.41	7.3%
Real Estate (VNQ)	5.1%	20.7%	0.22	17.9%
Bitcoin (BTCUSD)	67.4%	66.9%	1.07	17.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	71.4 Mil
Short Interest: % Change Since 3152026	-14.3%
Average Daily Volume	28.5 Mil
Days-to-Cover Short Interest	2.5 days
Basic Shares Quantity	227.1 Mil
Short % of Basic Shares	31.4%

Returns Analyses

	Title
0	How Low Can Hims & Hers Health Stock Really Go?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/23/2026	-0.3%	6.3%	37.6%
11/3/2025	-3.6%	-7.5%	-9.8%
8/4/2025	-12.4%	-21.1%	-29.8%
5/5/2025	18.1%	31.8%	28.0%
2/24/2025	-22.3%	-20.7%	-27.8%
11/4/2024	-0.6%	34.3%	63.4%
8/5/2024	-5.4%	-10.5%	-18.1%
5/6/2024	6.0%	10.6%	86.7%
...
SUMMARY STATS
# Positive	8	11	11
# Negative	12	9	9
Median Positive	14.9%	11.5%	37.6%
Median Negative	-5.6%	-9.9%	-22.7%
Max Positive	31.0%	43.4%	86.7%
Max Negative	-22.3%	-21.1%	-30.0%

	Forward Returns
2/23/2026	-0.3%	6.3%	37.6%
11/3/2025	-3.6%	-7.5%	-9.8%
8/4/2025	-12.4%	-21.1%	-29.8%
5/5/2025	18.1%	31.8%	28.0%
2/24/2025	-22.3%	-20.7%	-27.8%
11/4/2024	-0.6%	34.3%	63.4%
8/5/2024	-5.4%	-10.5%	-18.1%
5/6/2024	6.0%	10.6%	86.7%
2/26/2024	31.0%	43.4%	54.3%
11/6/2023	11.0%	11.5%	41.7%
8/7/2023	-5.8%	-9.9%	-12.5%
5/8/2023	-10.1%	-9.1%	-22.7%
2/27/2023	16.8%	4.4%	2.7%
11/7/2022	19.7%	30.5%	51.5%
8/8/2022	-5.1%	8.2%	-2.4%
5/9/2022	-6.5%	-6.5%	13.2%
2/22/2022	13.1%	20.2%	25.7%
11/10/2021	-4.0%	1.2%	-23.9%
8/11/2021	10.8%	-2.6%	15.1%
3/18/2021	-9.7%	-18.6%	-30.0%
SUMMARY STATS
# Positive	8	11	11
# Negative	12	9	9
Median Positive	14.9%	11.5%	37.6%
Median Negative	-5.6%	-9.9%	-22.7%
Max Positive	31.0%	43.4%	86.7%
Max Negative	-22.3%	-21.1%	-30.0%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/23/2026	10-K
09/30/2025	11/03/2025	10-Q
06/30/2025	08/04/2025	10-Q
03/31/2025	05/05/2025	10-Q
12/31/2024	02/24/2025	10-K
09/30/2024	11/04/2024	10-Q
06/30/2024	08/05/2024	10-Q
03/31/2024	05/06/2024	10-Q
12/31/2023	02/26/2024	10-K
09/30/2023	11/06/2023	10-Q
06/30/2023	08/07/2023	10-Q
03/31/2023	05/08/2023	10-Q
12/31/2022	02/27/2023	10-K
09/30/2022	11/07/2022	10-Q
06/30/2022	08/08/2022	10-Q
03/31/2022	05/09/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/23/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Revenue	600.00 Mil	612.50 Mil	625.00 Mil
Q1 2026 Adjusted EBITDA	35.00 Mil	45.00 Mil	55.00 Mil
Q1 2026 Adjusted EBITDA Margin	6.0%	7.5%	9.0%
2026 Revenue	2.70 Bil	2.80 Bil	2.90 Bil	19.4%		Higher New	Actual: 2.35 Bil for 2025
2026 Adjusted EBITDA	300.00 Mil	337.50 Mil	375.00 Mil	8.2%		Higher New	Actual: 312.00 Mil for 2025
2026 Adjusted EBITDA Margin	11.0%	12.0%	13.0%	-7.7%	-1.0%	Lower New	Actual: 13.0% for 2025

Prior: Q3 2025 Earnings Reported 11/3/2025

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q4 2025 Revenue	605.00 Mil	615.00 Mil	625.00 Mil
Q4 2025 Adjusted EBITDA	55.00 Mil	60.00 Mil	65.00 Mil
Q4 2025 Adjusted EBITDA Margin	9.0%	9.5%	10.0%
2025 Revenue	2.33 Bil	2.35 Bil	2.35 Bil	-0.2%		Lowered	Guidance: 2.35 Bil for 2025
2025 Adjusted EBITDA	307.00 Mil	312.00 Mil	317.00 Mil	-1.0%		Lowered	Guidance: 315.00 Mil for 2025
2025 Adjusted EBITDA Margin		13.0%		-3.7%	-0.5%	Lowered	Guidance: 13.5% for 2025

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	12232025	35.72	23,090	824,710	3,369,311	Form
2	Chi, Michael	Chief Operating Officer	Direct	Sell	12182025	36.71	13,750	504,762	11,202,460	Form
3	Autor, Deborah M	Chief Policy Officer	Direct	Sell	12182025	36.71	7,054	258,952	226,684	Form
4	Carroll, Patrick Harrison	Chief Medical Officer	Direct	Sell	12182025	36.71	10,021	367,871	6,238,497	Form
5	Becklund, Irene	PAO	Direct	Sell	12182025	36.71	8,411	308,768	78,045	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	12232025	35.72	23,090	824,710	3,369,311	Form
2	Chi, Michael	Chief Operating Officer	Direct	Sell	12182025	36.71	13,750	504,762	11,202,460	Form
3	Autor, Deborah M	Chief Policy Officer	Direct	Sell	12182025	36.71	7,054	258,952	226,684	Form
4	Carroll, Patrick Harrison	Chief Medical Officer	Direct	Sell	12182025	36.71	10,021	367,871	6,238,497	Form
5	Becklund, Irene	PAO	Direct	Sell	12182025	36.71	8,411	308,768	78,045	Form
6	Perez, Garcia Andrea G		Direct	Sell	12102025	39.17	2,500	97,925	3,140,102	Form
7	Boughton, Soleil	Chief Legal Officer	Direct	Sell	11252025	35.22	2,631	92,664	5,396,584	Form
8	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	11192025	36.81	23,187	853,490	2,585,170	Form
9	Boughton, Soleil	Chief Legal Officer	Direct	Sell	11122025	42.53	2,637	112,152	6,628,556	Form
10	Boughton, Soleil	Chief Legal Officer	Direct	Sell	10282025	50.10	2,637	132,114	7,940,499	Form
11	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	10202025	57.13	11,592	662,222	4,012,179	Form
12	Dudum, Andrew	Chief Executive Officer	Direct	Sell	10202025	62.78	128,127	8,043,237	5,808,178	Form
13	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	10202025	62.83	47,534	2,986,761	2,986,133	Form
14	Chi, Michael	Chief Commercial Officer	Direct	Sell	10142025	58.25	900	52,425	16,976,322	Form
15	Boughton, Soleil	Chief Legal Officer	Direct	Sell	10142025	54.38	2,637	143,400	8,762,249	Form
16	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	10072025	57.72	11,595	669,232	4,053,601	Form
17	Chi, Michael	Chief Commercial Officer	Direct	Sell	10022025	56.00	250	14,000	16,320,584	Form
18	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	9302025	60.20	85,000	5,116,924	4,227,903	Form
19	Boughton, Soleil	Chief Legal Officer	Direct	Sell	9302025	58.79	2,637	155,029	9,627,862	Form
20	Chi, Michael	Chief Commercial Officer	Direct	Sell	9252025	56.52	2,100	118,692	16,472,132	Form
21	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	9242025	57.74	23,584	1,361,766	6,085,912	Form
22	Boughton, Soleil	Chief Legal Officer	Direct	Sell	9192025	50.50	2,637	133,168	8,403,402	Form
23	Carroll, Patrick Harrison	Chief Medical Officer	Direct	Sell	9192025	50.50	10,021	506,060	8,581,970	Form
24	Becklund, Irene	PAO	Direct	Sell	9192025	50.50	8,410	424,705	71,609	Form
25	Chi, Michael	Chief Commercial Officer	Direct	Sell	9192025	50.50	13,749	694,324	15,005,520	Form
26	Dudum, Andrew	Chief Executive Officer	Direct	Sell	9192025	50.57	65,110	3,292,906	4,820,508	Form
27	Chi, Michael	Chief Commercial Officer	Direct	Sell	9172025	56.00	4,150	232,400	15,604,624	Form
28	Dudum, Andrew	Chief Executive Officer	Direct	Sell	9172025	53.48	128,127	6,852,300	8,579,614	Form
29	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	9172025	53.27	47,534	2,532,325	5,064,118	Form
30	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	9172025	55.35	145,000	8,026,076	7,139,554	Form
31	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	8282025	43.69	11,581	505,968	5,103,196	Form
32	Boughton, Soleil	Chief Legal Officer	Direct	Sell	8262025	44.53	2,571	114,487	6,699,538	Form
33	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	8202025	45.05	47,534	2,141,492	6,424,026	Form
34	Dudum, Andrew	Chief Executive Officer	Direct	Sell	8202025	45.06	128,127	5,773,242	4,033,704	Form
35	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	8142025	48.05	11,581	556,420	5,612,049	Form
36	Boughton, Soleil	Chief Legal Officer	Direct	Sell	8122025	51.64	2,572	132,818	7,902,004	Form
37	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Heritage Trust UAD 8-10-2021	Sell	8112025	50.58	660,000	33,384,120	112,027,446	Form
38	Carroll, Patrick Harrison	Chief Medical Officer	Direct	Sell	8082025	53.58	60,000	3,214,878	9,105,606	Form
39	Chi, Michael	Chief Commercial Officer	Direct	Sell	8042025	67.00	26,350	1,765,450	18,669,818	Form
40	Chi, Michael	Chief Commercial Officer	Direct	Sell	8042025	64.44	250	16,110	17,956,464	Form
41	Boughton, Soleil	Chief Legal Officer	Direct	Sell	7292025	58.70	2,572	150,976	9,133,309	Form
42	Chi, Michael	Chief Commercial Officer	Direct	Sell	7252025	56.00	13,750	770,000	15,604,624	Form
43	Chi, Michael	Chief Commercial Officer	Direct	Sell	7252025	57.52	2,100	120,792	16,028,178	Form
44	Dudum, Andrew	Chief Executive Officer	Direct	Sell	7232025	49.54	125,335	6,208,637	4,572,848	Form
45	Dudum, Andrew	Chief Executive Officer	Direct	Sell	7182025	50.58	2,792	141,217	4,669,099	Form
46	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	7182025	50.25	47,534	2,388,817	9,554,767	Form
47	Boughton, Soleil	Chief Legal Officer	Direct	Sell	7152025	47.82	2,572	122,993	7,563,450	Form
48	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	7152025	47.70	11,581	552,418	2,579,828	Form
49	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	7082025	46.67	11,581	540,498	2,710,564	Form
50	Boughton, Soleil	Chief Legal Officer	Direct	Sell	7012025	50.50	2,572	129,886	8,117,218	Form
51	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	6242025	47.25	23,107	1,091,766	2,987,132	Form
52	Chi, Michael	Chief Commercial Officer	Direct	Sell	6172025	59.75	17,102	1,021,844	16,649,576	Form
53	Dudum, Andrew	Chief Executive Officer	Direct	Sell	6172025	56.76	128,127	7,271,950	9,093,131	Form
54	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	6172025	56.51	47,534	2,686,300	13,430,933	Form
55	Dudum, Andrew	Chief Executive Officer	Direct	Sell	6172025	59.22	65,110	3,855,542	5,631,720	Form
56	Boughton, Soleil	Chief Legal Officer	Direct	Sell	6172025	56.80	5,451	309,617	9,422,041	Form
57	Boughton, Soleil	Chief Legal Officer	Direct	Sell	6172025	59.75	2,572	153,677	9,757,713	Form
58	Becklund, Irene	PAO	Direct	Sell	6172025	59.75	8,485	506,979	42,542	Form
59	Chi, Michael	Chief Commercial Officer	Direct	Sell	6112025	57.00	5,600	319,200	14,613,660	Form
60	Chi, Michael	Chief Commercial Officer	Direct	Sell	6092025	56.00	5,100	285,600	14,368,480	Form
61	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	5302025	52.98	11,581	613,537	2,074,244	Form
62	Boughton, Soleil	Chief Legal Officer	Direct	Sell	5292025	55.87	3,233	180,628	8,558,949	Form
63	Becklund, Irene	PAO	Direct	Sell	5272025	53.51	5,071			Form
64	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	5192025	60.22	11,581	697,462	6,854,534	Form
65	Dudum, Andrew	Chief Executive Officer	Direct	Sell	5192025	58.40	128,127	7,482,414	5,215,621	Form
66	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	5192025	58.25	47,534	2,768,974	16,613,261	Form
67	Baird, Melissa	Chief Operating Officer	Direct	Sell	5132025	56.02	33,333	1,867,376	45,102,236	Form
68	Boughton, Soleil	Chief Legal Officer	Direct	Sell	5132025	56.00	3,235	181,160	8,759,912	Form
69	Boughton, Soleil	Chief Legal Officer	Direct	Sell	4302025	30.19	3,236	97,695	4,820,196	Form
70	Dudum, Andrew	Chief Executive Officer	Direct	Sell	4302025	30.19	41,667	1,257,760	2,780,221	Form
71	Dudum, Andrew	Chief Executive Officer	Direct	Sell	4302025	36.39	50,000	1,819,310	3,351,278	Form
72	Baird, Melissa	Chief Operating Officer	Direct	Sell	4232025	25.78	33,333	859,256	20,753,382	Form
73	Becklund, Irene	PAO	Direct	Sell	4232025	26.49	2,936	77,775	134,331	Form
74	Dudum, Andrew	Chief Executive Officer	Direct	Sell	4182025	28.04	36,460	1,022,453	2,582,858	Form
75	Dudum, Andrew	Chief Executive Officer	Held by Trustee of Dudum Family Community Property Trust	Sell	4182025	28.23	47,534	1,342,094	9,394,375	Form
76	Boughton, Soleil	Chief Legal Officer	Direct	Sell	4162025	45.14	4,151	187,376	7,499,289	Form
77	Boughton, Soleil	Chief Legal Officer	Direct	Sell	4162025	28.72	3,236	92,938	4,678,431	Form
78	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	4162025	28.50	11,581	330,082	3,390,598	Form
79	Baird, Melissa	Chief Operating Officer	Direct	Sell	4102025	27.32	33,337	910,687	21,992,950	Form
80	Becklund, Irene	PAO	Direct	Sell	4042025	28.78	2,203	63,402	230,441	Form
81	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	4042025	29.26	11,581	338,833	3,630,998	Form
82	Boughton, Soleil	Chief Legal Officer	Direct	Sell	4012025	27.77	3,236	89,864	4,728,814	Form
83	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	1212026	30.34	9,067	275,114	2,779,870	Form
84	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	2042026	26.44	5,262	139,108	2,422,014	Form
85	Boughton, Soleil	Chief Legal Officer	Direct	Sell	3022026	15.21	4,651	70,742	6,707,184	Form
86	Becklund, Irene	PAO	Direct	Sell	3182026	24.69	5,529	136,511	216,087	Form
87	Boughton, Soleil	Chief Legal Officer	Direct	Sell	3182026	24.69	4,812	118,808	7,625,037	Form
88	Chi, Michael	Chief Operating Officer	Direct	Sell	3182026	24.69	97,289	2,402,065	10,055,793	Form
89	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	3242026	23.77	9,217	219,067	7,576,881	Form
90	Okupe, Oluyemi	Chief Financial Officer	Direct	Sell	4072026	19.98	3,975	79,409	6,368,448	Form

HIMS Trade Sentinel

Stock Conviction

null

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing HIMS?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What HIMS Makes & Who Pays

TTM figures based on

HIMS Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Hims & Hers Health (HIMS)

Market Price (4/11/2026): $19.43 | Market Cap: $4.4 BilSector: Health Care | Industry: Health Care Services

Hims & Hers Health (HIMS)

Market Price (4/11/2026): $19.43Market Cap: $4.4 BilSector: Health CareIndustry: Health Care Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Hims & Hers Health (HIMS)

Andrew Dudum

Yemi Okupe

Mike Chi

Dr. Patrick Carroll

Dheerja Kaur

Regulatory and Legal Scrutiny

Intense Competition

Reliance on Compounded Medications and Market Shifts

Addressable Markets for Hims & Hers Health (HIMS)

Interactive Breakdown

Better Bets vs. Hims & Hers Health (HIMS)

INDUSTRY: Health Care Services

Higher Op Mgn LTM (Value for HIMS: 4.5%)

Higher CFO/Rev LTM (Value for HIMS: 12.8%)

Higher FCF/Rev LTM (Value for HIMS: 2.4%)

Higher Total Yield (Value for HIMS: 2.9%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for HIMS: 64.6% | 1.9x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HIMS: 64.6% | 41.8x)

Higher Rev Chg LTM (Value for HIMS: 59.0%)

Higher Rev Chg 3Y Avg (Value for HIMS: 64.6%)

Higher Op Mgn LTM (Value for HIMS: 4.5%)

Higher CFO/Rev LTM (Value for HIMS: 12.8%)

Higher FCF/Rev LTM (Value for HIMS: 2.4%)

Higher Total Yield (Value for HIMS: 2.9%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for HIMS: 64.6% | 1.9x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HIMS: 64.6% | 41.8x)

Higher Rev Chg LTM (Value for HIMS: 59.0%)

Higher Rev Chg 3Y Avg (Value for HIMS: 64.6%)

Higher Op Mgn LTM (Value for HIMS: 4.5%)

Higher CFO/Rev LTM (Value for HIMS: 12.8%)

Higher FCF/Rev LTM (Value for HIMS: 2.4%)

Higher Total Yield (Value for HIMS: 2.9%)

Best Bets in Health Care

P/EBIT (Value for HIMS: 41.8x)

P/E (Value for HIMS: 34.4x)

Rev Chg 3Y Avg (Value for HIMS: 64.6%)

Rev Chg LTM (Value for HIMS: 59.0%)

Rev Chg Q (Value for HIMS: 28.4%)

FCF/Rev 3Y Avg (Value for HIMS: 7.1%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Market Price (4/11/2026): $19.43 | Market Cap: $4.4 Bil
Sector: Health Care | Industry: Health Care Services

Market Price (4/11/2026): $19.43
Market Cap: $4.4 Bil
Sector: Health Care
Industry: Health Care Services